The present disclosure is directed to pharmaceutical packages which include a coating that comprises polycyanurate, and methods for the production of such. In one or more embodiments of the present disclosure, a pharmaceutical package may comprise a glass container comprising a first surface and a second surface opposite the first surface. The first surface may be an outer surface of the glass container. The pharmaceutical package may further comprise a coating positioned over at least a portion of the first surface of the glass container. The coating may comprise polycyanurate.

A pharmaceutically acceptable insulin premix formulation contains about 0.1-10.0 Unit/mL of insulin for intravenous administration and preferably further contains a tonicity adjuster. The methods for making and using such formulation are also provided. The pharmaceutically acceptable insulin premix formulation may be aseptically filled into a flexible container assembly to form a pharmaceutical insulin premix product. The insulin premix product can be a sterile and ready-to-use aqueous solution for glycemic control in an individual with metabolic disorders through intravenous infusion. The insulin premix product is unexpectedly stable when freshly prepared and also during its shelf-life of storage at refrigeration temperatures of 2° C. to 5° C. for 24 months followed by additional 30 days at room temperatures of 23° C. to 27° C., even without any added preservative, any added zinc, any added surfactant or any other added stabilizing excipient.

Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d.sub.1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness T.sub.i that is less than or equal to 0.85*s.sub.1, wherein s.sub.1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

The present invention provides ophthalmic pharmaceutical compositions of the compound of Formula (I).

##STR(I)##

A glass vial includes a base including a boron-containing multicomponent glass and a vial opening and holds a liquid active pharmaceutical ingredient formulation. The glass vial has a total volume of <4.5 mL. A filling level of the glass vial with the active pharmaceutical ingredient formulation is not more than 0.25 and a concentration of boron ions, measured at a measurement site below a plane of a middle of the glass vial using a concentration depth profile at a depth in a range from 10 to 30 nm, has a value, averaged over the measurements of the concentration depth profile, that has an excess increase of not more than 30% compared to a concentration of boron ions measured using a concentration depth profile at a depth in a range from 10 to 30 nm with a measurement site in the plane of the middle of the glass vial.

A novel device, method and kit for reconstitution of a solid or semi-solid pharmaceutical composition by a negative pressure differential includes (i) a first adapter with a first connector, a first peripheral wall wherein the first adapter is coupled to the first vial by means of a first connector; (ii) a second adapter with a second connector, a second peripheral wall wherein the second adapter is coupled to the second vial by means of a second connector; (iii) a transfer port wherein the transfer port includes a first end ending in first adapter to gain access to first vial and a second end ending in second adapter to gain access to second vial; wherein the first adapters and the second adapter are joined together in vertical direction by means of horizontal wall; wherein the adapter connected to the vials by means of the ends.

A receptacle for receiving a bottom portion of a container having an outer surface and a bottom surface, the receptacle including a structure including a wall comprising at least one light transmission property, a top surface and a side surface; and a light emitting device configured to be disposed such that a light emission of the light emitting device is transmissible through the top surface of the structure onto the outer surface of the container and through the bottom surface of the container to illuminate the outer surface of the container.

Provided is a gas fill fixture for use in lyophilization, a related system and method. The gas fill fixture includes a chassis, fill indicator and a lid, such that the chassis and lid together form a cavity for receiving a flexible lyophilization container. The system includes a lyophilization container, a lyophilizer and a gas fill fixture incorporating a chassis, a fill indicator and a lid. The method includes process steps for using the system to lyophilize a fluid.

A quartz glass container is shown and described herein. The quartz glass container exhibits a low concentration of surface defects on an inner surface of the container. In aspects hereof, the container may have a surface defect density of 50 or fewer surface defects per square centimeter within a 1 cm band centered 1 cm from the base of the container.

In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated travelers diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection. In alternative embodiments, the invention provides pharmaceuticals and products (articles) of manufacture for delivering these compositions and formulations to an individual, e.g., a human or an animal. The invention also provides devices for delivering a fecal material to a patient.